Literature DB >> 19247814

Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.

Tingting Ren1, Beihai Jiang, Xiaofang Xing, Bin Dong, Lirong Peng, Lin Meng, Huiyu Xu, Chengchao Shou.   

Abstract

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in several human cancers and associated with tumor progression, invasion and metastasis. However, the correlation between PRL-3 expression and clinical outcome in ovarian cancer has not been studied. In the present study, we investigated the expression of PRL-3 in 119 ovarian cancers and 30 normal ovarian tissues by immunohistochemistry with an anti-PRL-3 mouse monoclonal antibody 3B6, and analyzed its relationship with clinicopathologic factors and survival. The results demonstrated that PRL-3 expression was significantly higher in ovarian cancers compared to normal ovarian tissues (P < 0.001). PRL-3 expression is not correlated with patient age, menstruation, tumor size, histological type, residual tumor, or other clinical findings. The patients with PRL-3-positive tumors had a significant poor prognosis than those with PRL-3-negative tumors. Univariate analysis identified PRL-3 expression as a poor outcome predictor (HR 1.925, 95% CI, 1.046-3.544, P = 0.035). Multivariate analysis indicated that PRL-3 expression was an independent prognostic factor of borderline significance (HR 1.695, 95% CI, 0.914-3.145, P = 0.094). Our results suggest that PRL-3 may serve as a valuable marker for diagnosis of ovarian cancer and as a potential independent prognostic factor for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247814     DOI: 10.1007/s12253-009-9153-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

Review 1.  Dual-specificity phosphatases as targets for antineoplastic agents.

Authors:  Michael A Lyon; Alexander P Ducruet; Peter Wipf; John S Lazo
Journal:  Nat Rev Drug Discov       Date:  2002-12       Impact factor: 84.694

2.  Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.

Authors:  Lirong Peng; Yan Li; Ling Meng; Chengchao Shou
Journal:  Hybrid Hybridomics       Date:  2004-02

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.

Authors:  L Wang; L Peng; B Dong; L Kong; L Meng; L Yan; Y Xie; C Shou
Journal:  Ann Oncol       Date:  2006-07-27       Impact factor: 32.976

5.  Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.

Authors:  Jie Li; Ke Guo; Vicki Wei Chyi Koh; Jing Ping Tang; Bin Qi Gan; Hong Shi; Hui Xiang Li; Qi Zeng
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

6.  High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.

Authors:  U A Miskad; S Semba; H Kato; Y Matsukawa; Y Kodama; E Mizuuchi; N Maeda; K Yanagihara; H Yokozaki
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

7.  The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.

Authors:  Lirong Peng; Jinying Ning; Ling Meng; Chengchao Shou
Journal:  J Cancer Res Clin Oncol       Date:  2004-05-06       Impact factor: 4.553

8.  Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.

Authors:  Upik Anderiani Miskad; Shuho Semba; Hirotaka Kato; Hiroshi Yokozaki
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

9.  Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.

Authors:  W Mastropaolo; Z Fernandez; E L Miller
Journal:  Clin Chem       Date:  1986-11       Impact factor: 8.327

10.  Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

Authors:  Xiaopeng Wu; Hu Zeng; Xianming Zhang; Ying Zhao; Haibo Sha; Xiaomei Ge; Minyue Zhang; Xiang Gao; Qiang Xu
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

View more
  28 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 2.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

3.  Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.

Authors:  Yunpeng Bai; Zhi-Hong Yu; Sijiu Liu; Lujuan Zhang; Ruo-Yu Zhang; Li-Fan Zeng; Sheng Zhang; Zhong-Yin Zhang
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

4.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

5.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 6.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

Review 7.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

Review 8.  Intracellular antigens as targets for antibody based immunotherapy of malignant diseases.

Authors:  Yangyang Wang; Xinhui Wang; Cristina R Ferrone; Joseph H Schwab; Soldano Ferrone
Journal:  Mol Oncol       Date:  2015-10-30       Impact factor: 6.603

9.  Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.

Authors:  Yijun Xu; Mingchen Zhu; Shuhong Zhang; Hui Liu; Tao Li; Chengyong Qin
Journal:  Pathol Oncol Res       Date:  2009-09-09       Impact factor: 3.201

10.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Authors:  Lirong Peng; Xiaofang Xing; Weijun Li; Like Qu; Lin Meng; Shenyi Lian; Beihai Jiang; Jian Wu; Chengchao Shou
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.